Bio-Path Holdings Expands Global Patent Portfolio
15 Abril 2024 - 6:00AM
Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company
leveraging its proprietary DNAbilize® liposomal delivery and
antisense technology to develop a portfolio of targeted nucleic
acid cancer drugs, today announced the receipt of newly issued
patents in Mexico, Australia and Japan, and updated investors on
the extent of its global intellectual property portfolio.
Bio-Path has expanded its intellectual property
portfolio by filing patent applications that are applicable to its
technology and business strategy. Bio-Path’s patent portfolio
currently includes five issued patents in the U.S. and 54 issued
patents in foreign jurisdictions, providing protection in 21
countries.
“We continue our efforts to build protection
around our platform as it safeguards our technology, is a deterrent
to would-be competitors and creates value around our core
competencies,” said Peter Nielsen, Chief Executive Officer of
Bio-Path. “These efforts are designed to protect our investments
and advance our clinical programs to bring new medicines to
patients suffering with cancer.”
Bio-Path’s composition of matter patents are
intended to protect encroachment from third parties on its
proprietary products. This technology is solely owned by Bio-Path.
These composition patents, including composition and methods of use
patents covering the DNAbilize technology, should allow the Company
to apply its core technology to new protein targets and receive an
additional 20-years of patent exclusivity. On this basis, Bio-Path
has one additional patent application allowed in the U.S. and five
additional patent applications allowed in foreign jurisdictions,
for a total of six additional patent grants expected this year.
Further, the Company has five pending patent applications in the
U.S. and 46 pending patent applications in key foreign
jurisdictions across six families of applications, for a total of
51 pending applications.
Newly issued patents have been granted in
Mexico, Australia, and Japan. Instituto Mexicano de la Propriedad
Industrial (IMPI) has issued MX 409482 titled, “P-ethoxy nucleic
acids for IGF-1R inhibition.” In addition, IP Australia issued
three new patents: AU 2018255352 titled, “P-ethoxy nucleic acids
for STAT3 inhibition;” AU 2018255353 titled, “P-ethoxy nucleic
acids for IGF-1R inhibition;” and AU 2018254468 titled, “P-ethoxy
nucleic acids for BCL2 inhibition.” Finally, the Japanese Patent
Office has issued JP 7441002 titled, “P-ethoxy nucleic acids for
liposomal formulation.”
About Bio-Path Holdings,
Inc.
Bio-Path is a biotechnology company developing
DNAbilize®, a novel technology that has yielded a pipeline of RNAi
nanoparticle drugs that can be administered with a simple
intravenous transfusion. Bio-Path’s lead product candidate,
prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2
study for blood cancers, and BP1001-A, a drug product modification
of prexigebersen, is in a Phase 1/1b study for solid tumors. The
Company’s second product, BP1002, which targets the Bcl-2 protein,
is being evaluated for the treatment of blood cancers and solid
tumors, including lymphoma and acute myeloid leukemia. In addition,
an IND application is expected to be filed for BP1003, a novel
liposome-incorporated STAT3 antisense oligodeoxynucleotide
developed by Bio-Path as a specific inhibitor of STAT3.
For more information, please visit the Company's
website at http://www.biopathholdings.com.
Forward-Looking Statements
This press release contains forward-looking
statements that are made pursuant to the safe harbor provisions of
the federal securities laws. These statements are based on
management's current expectations and accordingly are subject to
uncertainty and changes in circumstances. Any express or implied
statements contained in this press release that are not statements
of historical fact may be deemed to be forward-looking statements.
Any statements that are not historical facts contained in this
release are forward-looking statements that involve risks and
uncertainties, including Bio-Path’s ability to raise needed
additional capital on a timely basis in order for it to continue
its operations, have success in the clinical development of its
technologies, the timing of enrollment and release of data in such
clinical studies, the accuracy of such data, limited patient
populations of early stage clinical studies and the possibility
that results from later stage clinical trials with much larger
patient populations may not be consistent with earlier stage
clinical trials, the maintenance of intellectual property rights,
that patents relating to existing or future patent applications
will be issued or that any issued patents will provide meaningful
protection of our drug candidates, the impact, risks and
uncertainties related to global pandemics, including the COVID-19
pandemic, and actions taken by governmental authorities or others
in connection therewith, and such other risks which are identified
in Bio-Path's most recent Annual Report on Form 10-K, in any
subsequent quarterly reports on Form 10-Q and in other reports that
Bio-Path files with the Securities and Exchange Commission from
time to time. These documents are available on request from
Bio-Path Holdings or at www.sec.gov. Bio-Path disclaims any
intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
Contact Information:
Investors
Will O’Connor Stern Investor Relations,
Inc.212-362-1200will@sternir.com
Doug Morris Investor Relations Bio-Path
Holdings, Inc. 832-742-1369
Bio Path (NASDAQ:BPTH)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Bio Path (NASDAQ:BPTH)
Gráfica de Acción Histórica
De May 2023 a May 2024